Home Cart Sign in  
Chemical Structure| 136164-66-4 Chemical Structure| 136164-66-4

Structure of E3330
CAS No.: 136164-66-4

Chemical Structure| 136164-66-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

E3330 (APX-3330) is a direct, orally active, selective inhibitor of Ape-1 (apurinic/apyrimidinic endonuclease 1)/Ref-1 (redox factor-1). E3330 inhibits the activity of NF-κB, AP-1, and HIF-1α in pancreatic cancer tissues. E3330 has anticancer activity.

Synonyms: APX-3330

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of E3330

CAS No. :136164-66-4
Formula : C21H30O6
M.W : 378.46
SMILES Code : CCCCCCCCC/C(C(O)=O)=C\C1=C(C)C(C(OC)=C(OC)C1=O)=O
Synonyms :
APX-3330
MDL No. :MFCD00901331

Safety of E3330

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H411
Precautionary Statements:P273-P312-P501

Related Pathways of E3330

epigenetics
DNA
RTK
MAPK
pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
XPA1 cells 20-30 µM 72 hours E3330 significantly inhibits the growth of XPA1 cells Mol Cancer Ther. 2008 Jul;7(7):2012-21.
PANC1 cells 20-30 µM 72 hours E3330 significantly inhibits the growth of PANC1 cells Mol Cancer Ther. 2008 Jul;7(7):2012-21.
Dental Papilla Cells (DPCs) 10 µM 1 day, 3 days, 6 days, 9 days E3330 promotes the osteo/odontogenic differentiation capacity of DPCs by inhibiting the redox function of Ape1 and activating the canonical Wnt signaling pathway. Sci Rep. 2015 Dec 7;5:17483.
HepG2 cells 10-100 µM 12 hours E3330 synergistically increased cytotoxicity when combined with TRAIL, TNFα, and Fas ligand World J Gastroenterol. 2005 Oct 28;11(40):6258-61.
SKHep1 cells 10-100 µM 12 hours E3330 synergistically increased cytotoxicity when combined with TRAIL, TNFα, and Fas ligand World J Gastroenterol. 2005 Oct 28;11(40):6258-61.
HLE cells 10-100 µM 12 hours E3330 decreased NFκB levels in a dose-dependent manner in HLE cells stimulated by TNFα and TRAIL World J Gastroenterol. 2005 Oct 28;11(40):6258-61.
Retinal vascular endothelial cells (RVECs) 10, 25, 50, 100 µM 2 days Evaluated the effect of E3330 on RVEC proliferation, showing dose-dependent inhibition of RVEC growth Antioxid Redox Signal. 2008 Nov;10(11):1853-67.
FLO-1 cells 40 µM 20 minutes To investigate the effect of E3330 on ABS-induced E-cadherin cleavage and EMT, results showed that E3330 downregulated MMP14 and abrogated ABS-induced EMT. Gut. 2023 Dec 7;73(1):47-62.
OE19 cells 40 µM 20 minutes To investigate the effect of E3330 on ABS-induced E-cadherin cleavage and EMT, results showed that E3330 downregulated MMP14 and abrogated ABS-induced EMT. Gut. 2023 Dec 7;73(1):47-62.
OE33 cells 40 µM 20 minutes To investigate the effect of E3330 on ABS-induced E-cadherin cleavage and EMT, results showed that E3330 downregulated MMP14 and abrogated ABS-induced EMT. Gut. 2023 Dec 7;73(1):47-62.
OE33 cells 100 µM 20 minutes To investigate the inhibitory effect of E3330 on APE1 redox function, it was found that E3330 treatment led to a significant decrease in NRF2 transcriptional activity. Redox Biol. 2021 Jul;43:101970.
FLO1 cells 100 µM 20 minutes To investigate the inhibitory effect of E3330 on APE1 redox function, it was found that E3330 treatment led to a significant decrease in NRF2 transcriptional activity. Redox Biol. 2021 Jul;43:101970.
CPB cells 100 µM 20 minutes To investigate the inhibitory effect of E3330 on APE1 redox function, it was found that E3330 treatment led to a significant decrease in NRF2 transcriptional activity. Redox Biol. 2021 Jul;43:101970.
Bone marrow-derived dendritic cells (BMDCs) 50 µM 24 hours E3330 up-regulated IL-12 p35 and p40 gene expression but decreased IL-12 secretion J Biol Chem. 2016 Nov 4;291(45):23672-23680.
Primate choroid endothelial cells (CECs) 25-100 µM 24 hours E3330 dose-dependently suppressed CEC proliferation, migration, and tube formation without noticeable cell toxicity. Invest Ophthalmol Vis Sci. 2014 Jun 26;55(7):4461-9.
3T3-L1 cells 50 µM 24 hours E3330 inhibited the redox function of APE1/Ref-1, increasing the mRNA and protein levels of C/EBP-α, PPAR-γ, and aP2, promoting adipocyte differentiation. Int J Mol Sci. 2023 Feb 7;24(4):3251.
Lin-negative bone marrow cells 0.5 µM 36~48 hours E3330 treatment of Tet2-KO Lin-negative bone marrow cells inhibits IL-6 induced cell survival Cell Stem Cell. 2018 Dec 6;23(6):833-849.e5.
Non-small cell lung cancer (NSCLC) cell lines 1.55 µM 4 days To evaluate the sensitivity of NSCLC cell lines to 6-thio-dG, finding 73/77 cell lines were sensitive and 4/77 were resistant. Mol Cancer Ther. 2017 Jul;16(7):1401-1411.
U937 monocyte-like cells 100 µM 4 hours To investigate the effects of E3330 on inflammatory response in U937 cells, results showed that E3330 treatment reduced cell viability and expression of pro-inflammatory cytokines. Front Cell Dev Biol. 2021 Sep 20;9:731588.
SKOV-3X ovarian cancer cells 80 µM (IC50) 40 hours To evaluate the inhibitory effect of E3330 and its analogues on NF-κB activity, results showed that E3330 and its analogues could inhibit NF-κB activation in a dose-dependent manner Antioxid Redox Signal. 2011 Apr 15;14(8):1387-401.
H1693 NSCLC cells 10 µM 4-7 days Overexpression of SLC43A3 in H1693 cells increased sensitivity to 6-thio-dG. Mol Cancer Ther. 2017 Jul;16(7):1401-1411.
HCC4017 NSCLC cells 10 µM 4-7 days Knockdown of SLC43A3 by siRNA resulted in resistance to 6-thio-dG in HCC4017 cells. Mol Cancer Ther. 2017 Jul;16(7):1401-1411.
Panc-1 cells 87 µM (ED50) 48 hours To evaluate the effect of E3330 on the proliferation of pancreatic cancer cells, results showed that E3330 significantly slowed cell growth in a dose-dependent manner. Mol Cancer Ther. 2011 Sep;10(9):1698-708.
CD4+ T cells 50 µM 72 hours E3330 had no significant effect on the induction of IFN-γ-producing T cells in the absence of APCs J Biol Chem. 2016 Nov 4;291(45):23672-23680.
OT-II mouse splenocytes 50 µM 72 hours E3330 significantly increased the induction of IFN-γ-producing OT-II T cells J Biol Chem. 2016 Nov 4;291(45):23672-23680.
PaCa-2 cells 135 µM (ED50) 72 hours To evaluate the effect of E3330 on the proliferation of pancreatic cancer cells, results showed that E3330 significantly slowed cell growth in a dose-dependent manner. Mol Cancer Ther. 2011 Sep;10(9):1698-708.
HPNE cells 50 µM 72 hours E3330 has no suppressive effects on the growth of HPNE cells Mol Cancer Ther. 2008 Jul;7(7):2012-21.
Panc-1 cells 67.5 µM 8-12 hours To evaluate the effect of E3330 on the adhesion ability of pancreatic cancer cells, results showed that E3330 significantly inhibited cell adhesion. Mol Cancer Ther. 2011 Sep;10(9):1698-708.
PaCa-2 cells 67.5 µM 8-12 hours To evaluate the effect of E3330 on the adhesion ability of pancreatic cancer cells, results showed that E3330 significantly inhibited cell adhesion. Mol Cancer Ther. 2011 Sep;10(9):1698-708.
H2087 NSCLC cells 3 µM 9-18 days Established acquired resistance model in H2087 cells, finding downregulation of SLC43A3 in resistant clones. Mol Cancer Ther. 2017 Jul;16(7):1401-1411.
OE33 cells 100 µM Overnight E3330 inhibited ABS-mediated increase in YAP1 protein levels J Exp Clin Cancer Res. 2022 Sep 1;41(1):264.
FLO-1 cells 100 µM Overnight E3330 inhibited ABS-mediated increase in YAP1 protein levels J Exp Clin Cancer Res. 2022 Sep 1;41(1):264.
Hey-C2 ovarian cancer cells 38.9 µM (LD50) To evaluate the effect of E3330 and its analogues on cell growth, results showed that E3330 and its analogues could inhibit cell growth Antioxid Redox Signal. 2011 Apr 15;14(8):1387-401.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PL2-IL1β transgenic Mice model Intraperitoneal injection 20 mg/kg 28 days To investigate the effect of E3330 on PDX tumor growth and invasion, results showed that E3330 suppressed tumor growth and invasion and restored E-cadherin expression levels. Gut. 2023 Dec 7;73(1):47-62.
Mice Tet2-KO mice Oral gavage 20 mg/kg Daily for 12 weeks Long-term treatment of juvenile Tet2-KO mice with E3330 rescues multiple phenotypic defects associated with Tet2 deficiency Cell Stem Cell. 2018 Dec 6;23(6):833-849.e5.
Mice PDX Mice model Oral gavage 20 mg/kg Every weekday for 4 weeks E3330 significantly inhibited PDX tumor volume and enhanced PDX mice survival J Exp Clin Cancer Res. 2022 Sep 1;41(1):264.
C57BL/6 mice Laser-induced CNV Mice model Intravitreal injection 200 μM (1 μL ) Single injection, lasted for 2 weeks E3330 significantly suppressed laser-induced CNV development without causing tissue toxicity. Invest Ophthalmol Vis Sci. 2014 Jun 26;55(7):4461-9.
C57BL/6J mice Laser-induced choroidal neovascularization (CNV) model Intravitreal injection 200 μM (1 μL ) Single injection, lasted for 2 weeks A single intravitreal injection of E3330 significantly reduced the area of laser-induced CNV lesions, indicating that E3330 attenuated damage to the RPE-Bruch's membrane complex in vivo. Redox Biol. 2014 Feb 21;2:485-94
NOD/SCID mice Pancreatic cancer xenograft model Intraperitoneal injection 25 mg/kg Twice daily for 10-12 days To evaluate the effect of E3330 on tumor growth in pancreatic cancer xenograft models in vivo, results showed that E3330 significantly inhibited tumor growth. Mol Cancer Ther. 2011 Sep;10(9):1698-708.
Nude mice T24 subcutaneous tumor model Intraperitoneal injection 50 mg/kg Every 12 hours for up to 12 days Inhibition of tumor growth Mol Cancer Ther. 2019 Nov;18(11):1947-1960

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.21mL

2.64mL

1.32mL

26.42mL

5.28mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories